Nkarta, Inc. (NASDAQ:NKTX – Free Report) – HC Wainwright lifted their Q2 2026 EPS estimates for Nkarta in a research report issued on Wednesday, May 13th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.39) per share for the quarter, up from their previous estimate of ($0.42). The consensus estimate for Nkarta’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Nkarta’s Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.43) EPS, FY2026 earnings at ($1.60) EPS and FY2027 earnings at ($1.95) EPS.
Several other equities analysts have also weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research report on Friday, March 27th. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Nkarta in a research report on Wednesday. Wall Street Zen lowered shares of Nkarta from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Mizuho reduced their price target on shares of Nkarta from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Nkarta has an average rating of “Moderate Buy” and a consensus target price of $11.33.
Nkarta Stock Performance
NKTX opened at $2.81 on Friday. The firm has a market cap of $201.03 million, a P/E ratio of -2.10 and a beta of 0.88. The firm has a 50-day moving average of $2.58 and a 200 day moving average of $2.23. Nkarta has a fifty-two week low of $1.63 and a fifty-two week high of $3.65.
Nkarta (NASDAQ:NKTX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.02.
Hedge Funds Weigh In On Nkarta
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NKTX. Abel Hall LLC bought a new position in Nkarta during the fourth quarter worth about $27,000. Dynamic Technology Lab Private Ltd bought a new position in Nkarta during the fourth quarter worth about $37,000. SG Americas Securities LLC boosted its position in Nkarta by 35.0% during the third quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock worth $49,000 after purchasing an additional 6,141 shares during the period. Bailard Inc. bought a new position in Nkarta during the third quarter worth about $61,000. Finally, Forefront Analytics LLC boosted its position in Nkarta by 41.0% during the third quarter. Forefront Analytics LLC now owns 39,452 shares of the company’s stock worth $82,000 after purchasing an additional 11,473 shares during the period. Institutional investors own 80.54% of the company’s stock.
About Nkarta
Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.
Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.
Featured Articles
- Five stocks we like better than Nkarta
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
